Safety of biologics in rheumatoid arthritis: Data from randomized controlled trials and registries

Biologics: Targets and Therapy

Volumn 9, Issue , 2015, Pages

  Codreanu, Catalin ^a   Damjanov, Nemanja ^b  

^a Center of Rheumatic Diseases   (Romania)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Adverse events; Biologic drugs; Biologic therapy; Infections; Malignancies; Pregnancy

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB;

ARTICLE; ASIA; CLINICAL RESEARCH; CONGESTIVE HEART FAILURE; DISEASE EXACERBATION; DISEASE REGISTRY; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EUROPE; EVIDENCE BASED MEDICINE; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; INFECTION; LEUKEMIA; LYMPHOMA; MEDICAL LITERATURE; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUBERCULOSIS; UNITED STATES; VIRUS REACTIVATION;

EID: 84922031869     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S68949     Document Type: Article

References (38)

1. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990;322(18):1277-1289.
2. Saleem B, Walsh CA, Emery P. Remission in inflammatory arthritis: a new immunological target. Immunotherapy. 2011;3(4):459-463.
3. van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol. 2009;5(10):531-541.
4. Curtis JR, Jain A, Askling J, et al. A comparison of patient characteristics and outcomes in selected European and US rheumatoid arthritis registries. Semin Arthritis Rheum. 2010;40(1):2-14. e1.
5. Geborek P, Crnkic M, Petersson IF, Saxne T; South Swedish Arthritis Treatment Group. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis. 2002;61(9):793-798.
6. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum. 2003;48(6): 1530-1542.
7. Kievit W, Fransen J, Oerlemans AJ, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis. 2007;66(11):1473-1478.
8. Global Tuberculosis Report 2014. Geneva: World Health Organization; 2014. Available from: http://www.who.int/tb/publications/global_report/en/. Accessed September 23, 2014.
9. Migliori GB, Centis R. Problems to control TB in eastern Europe and consequences in low incidence countries. Monaldi Arch Chest Dis. 2002;57(5-6):285-290.
10. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011(2):CD008794.
11. Askling J, Fored CM, Geborek P, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis. 2006;65(6): 707-712.
12. Mercer LK, Galloway JB, Lunt M, et al. The influence of anti-TNF therapy upon incidence of non-melanoma skin cancer (NMSC) in patients with rheumatoid arthritis (RA): results from the BSR Biologics Register (BSRBR) [abstract]. Arthritis Rheum. 2009;60 Suppl 10:2062.
13. Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010;12(1):R5.
14. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48(8):2122-2127.
15. Descalzo MÁ, Carmona L; Grupo de Estudio BIOBADASER. [Biobadaser 2.0: analysis and trends in 2009]. Rheumatol Clin. 2010;6(5):240-243. Spanish.
16. Kvien TK, Heiberg MS, Lie E, et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S188-S194.
17. Hetland ML. DANBIO: a nationwide registry of biological therapies in Denmark. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S205-S207.
18. Hetland ML, Christensen IJ, Tarp U, et al; All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22-32.
19. Damjanov N, Dimic A, Lazarevic M, Stefanovic D, Stankovic A; Rheumatology Association of Serbia. Disease activity and working disability in 1775 patients with rheumatoid arthritis - Data from National Registry of patients with Rheumatoid Arthritis in Serbia. Ann Rheum Dis. 2010;69(Suppl 3):671.
20. Ostojic P, Damjanov N, Dimic A, et al. Improved efficacy of rituximab in rheumatoid arthritis when administered regularly at six-month intervals - data from the Serbian registry (NARASS). Ann Rheum Dis. 2012;71(Suppl 3):670.
21. Pavelka K, Forejtová S, Stolfa J, et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol. 2009;27(6):958-963.
22. Marchesoni A, Zaccara E, Gorla R, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009;1173: 837-846.
23. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A; Swiss Clinical Quality Management Physicians. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 2009; 61(5):560-568.
24. Flouri I, Drosos A, Skopouli F, et al. Long term follow-up of RA patients of the Hellenic biologics registry: comparison of first versus second anti-TNFA therapy. Ann Rheum Dis. 2009;68(Suppl 3):430.
25. Komano Y, Tanaka M, Nanki T, et al; REAL Study Group. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol. 2011;38(7):1258-1264.
26. Kremer J. The CORRONA database. Ann Rheum Dis. 2005;64 Suppl 4:iv37-iv41.
27. Mariette X, Gottenberg JE, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford). 2011;50(1):222-229.
28. Gómez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007;57(5):756-761.
29. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70(11):1895-1904.
30. Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL; BSRBR Control Centre Consortiu, BSR Biologics Register. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70(5):823-826.
31. Strangfeld A, Zink A. [Safety of biologic therapy - results from the German biologics register RABBIT]. Dtsch Med Wochenschr. 2014;139(37):1817-1820. German.
32. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A; BSRBR Control Centre Consortium, Symmons DP; BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69(3):522-528.
33. Tubach F, Salmon D, Ravaud P, et al; Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60(7):1884-1894.
34. Gómez-Reino JJ, Carmona L; BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006; 8(1):R29.
35. Mok CC, Kwan C, Chan KY, Lee KL, Tam LS; Hong Kong Society of Rheumatology. Retention rate of the anti-TNF biologics in the treatment of rheumatic diseases and predictive factors for drug withdrawal: data from the Hong Kong Biologics Registry. Ann Rheum Dis. 2012; 71(Suppl 3):663.
36. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56(9):2886-2895.
37. Bansard C, Lequerré T, Daveau M, et al. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted? Rheumatology (Oxford). 2009;48(9):1021-1028.
38. Global Tuberculosis Report 2013. Geneva: World Health Organization; 2013. Available from: http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf. Accessed March 10, 2014.